BNP 1350

structure in first source
Also Known As:
BNP-1350; BNP1350
Networked: 5 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Prous, J R: 1 article (06/2007)
2. Bayés, M: 1 article (06/2007)
3. Rabasseda, X: 1 article (06/2007)
4. Centeno, Barbara: 1 article (04/2005)
5. Urbas, Patricia: 1 article (04/2005)
6. Deconti, Ronald C: 1 article (04/2005)
7. Sullivan, Patricia: 1 article (04/2005)
8. Sullivan, Daniel: 1 article (04/2005)
9. Berghorn, Elmer: 1 article (04/2005)
10. Liu, Zhenmei: 1 article (04/2005)

Related Diseases

1. Neoplasms (Cancer)
10/15/2000 - "In conclusion, BNP1350 shows a broad spectrum of activity in experimental human tumors and is a suitable candidate for oral treatment of cancer."
10/15/2000 - "New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer."
10/15/2000 - "We determined the efficacy of BNP1350 in experimental human colon cancer and compared its anti-tumor effects with those of CPT-11/SN-38. "
10/15/2000 - "BNP1350, 7-[(2-trimethylsilyl)ethyl]-20(S)-camptothecin, is a novel semi-synthetic, highly lipophilic, silicon-containing camptothecin and an inhibitor of topoisomerase I. It has been supercomputer engineered for superior oral bioavailability, superior lactone stability, broad anti-tumor activity, increased potency and insensitivity to Pgp/MRP/LRP drug resistance. "
06/01/2007 - "101M, 12B75; ABT-869, Agomelatine, Alvocidib hydrochloride, Amb a 1 ISS-1018, AMG-386, Andolast, AP-23573, Arsenic trioxide, ATI-7505; BAY-68-4986, Berberine chloride, BNP-1350, BrachySil, Brostallicin hydrochloride; Caldaret hydrate, Cancer vaccine, Cediranib, CHAMPION everolimus-eluting coronary stent, CP-751871; D-4F, Degarelix acetate, Dofequidar fumarate; Ecogramostim, Enzastaurin hydrochloride, Etaracizumab, Everolimus; Fluticasone furoate; Glucarpidase; Hochuekki-to, Human papillomavirus vaccine; Icatibant acetate, INO-1001, Interleukin-21, Irofulven, ISIS-301012, Ixabepilone; KRN-951; Lacosamide; Mecasermin, Mecasermin rinfabate, Mepolizumab, Mesna disulfide, m-NO-ASA; Nematode anticoagulant protein c2, Nilotinib, Nolatrexed dihydrochloride; O6-Benzylguanine; Pemetrexed disodium, Perifosine, Pertuzumab, Plitidepsin, Prasterone, PRO-2000/5, PX-12, Pyridoxal phosphate; Recombinant human soluble thrombomodulin, Retapamulin, Rinfabate, Rubitecan; Seliciclib, SR-271425, STA-4783; T- 2000, Telatinib, Temsirolimus, Terameprocol, Teverelix, Ticagrelor, Tipelukast, Tirapazamine; Uracil; Valspodar, Vatalanib succinate, Velimogene aliplasmid, Vitespen, Volociximab; XL-184."
2. Colonic Neoplasms (Colon Cancer)
3. Ovarian Neoplasms (Ovarian Cancer)
4. Melanoma (Melanoma, Malignant)
5. Carcinoma (Carcinomatosis)

Related Drugs and Biologics

1. irinotecan (Camptosar)
2. Camptothecin
3. Karenitecin
4. Topotecan (Hycamtin)
5. Type I DNA Topoisomerases (Topoisomerase I)
6. Succinic Acid (Succinate)
7. Thrombomodulin
8. Mesna (Coenzyme M)
9. Uracil
10. Silicon

Related Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)
2. Stents